Follow Alnylam Pharmaceuticals to never miss an important update.
The U.S. Food and Drug Administration approved Livsayis, a treatment for generalized myasthenia gravis, a chronic condition that causes muscle weakness and fatigue. While the drug was developed and will be sold by Regeneron, it was originally discovered using Alnylam's RNA interference technology, which works by silencing the specific genes that cause disease.
This is the seventh drug from Alnylam's platform to be approved in less than nine years. For a long-term owner, this is a clear sign that the company's core technology is reliable and repeatable. While Alnylam won't keep all the profits from this specific drug, the approval validates its ability to discover successful treatments that other major drugmakers are willing to bet on.
Source: Business Wire
Alnylam and its partner Regeneron shared early results for a new treatment targeting MASLD, a common condition where fat builds up in the liver and causes damage. In the first study on humans, a single injection quickly returned liver fat to normal levels and improved markers of liver health.
This is a positive step for Alnylam because it shows their gene-silencing technology works for this specific liver target. While this is only an early trial, the ability to normalize fat levels with one dose suggests the drug could eventually compete in a large and growing market for metabolic liver diseases.
Source: Business Wire
Alnylam shared new data from a long-term study of Amvuttra, its treatment for a specific type of heart disease caused by protein buildup. The results show that the drug continues to work well for patients five years after they started treatment, helping to keep them out of the hospital and reducing the risk of death.
This is important because Amvuttra is the company's biggest source of growth. Proving that the drug is safe and effective over many years helps cement its place as a standard treatment for this condition. For a long-term owner, this adds confidence that the drug's sales can remain steady as more patients stay on the therapy for longer periods.
Source: Business Wire
Alnylam's board authorized a plan to buy back up to $1 billion of its own shares, with about $500 million expected to be completed by the end of 2026. A buyback is when a company uses its cash to buy its own stock from the market, which reduces the total number of shares and makes each remaining share own a larger piece of the business.
Separately, the company announced that Tolga Tanguler, the Chief Commercialization Officer, will leave his role in December 2026. While leadership changes can sometimes be unsettling, this appears to be an orderly transition as the company moves into a new phase of growth. The buyback is a strong signal that management believes the stock is undervalued after its recent drop.
Source: 8-K filing
Alnylam will present new five-year clinical data for Amvuttra, its treatment for a specific type of heart disease, at the American Heart Association meeting starting November 6. These presentations are routine for biotech companies, but they provide the medical community with evidence of how well a drug works over several years. For long-term owners, this data helps confirm whether the drug can maintain its lead in a competitive market.
Source: Business Wire
Management consistently clears the bar they set, and the massive recent jump in profit suggests the business is scaling much faster than even the most bullish forecasts expected.
| Expectation | |
|---|---|
| EPS | $1.72 |
| Revenue | $1.52B |
Follow Alnylam Pharmaceuticals to get the latest and most important updates.
Follow ALNY